mAb Program &
Process Development

End-to-end CMC consulting for monoclonal antibody programs, from cell line design and upstream optimization through downstream purification,
formulation, and BLA-ready process documentation.

CHO, NS0 and transient expression systems Expression and Platform Strategy

Expression Systems

CHO-K1 and CHO-S
NS0 Systems
Transient HEK293
Stable Pool Generation

Upstream Operations

Clone Selection
Media Optimization
Fed-Batch Development
Bioreactor Scale-Up

Downstream Operations

Protein A Capture
CEX and AEX Polishing
HIC Step Design
Viral Clearance
UF/DF and Formulation

mAb Process Development From Cell Line Development to Commercial Manufacturing Readiness

DES Pharma supports monoclonal antibody programs from early cell line and process design through late-stage manufacturing readiness. Our teams work across common mAb formats and expression approaches, including CHO-based commercial platforms, NS0-derived systems where relevant, and transient expression models used to accelerate early development. We help sponsors translate product quality goals into practical manufacturing strategies that support consistency, scale, and regulatory readiness.

Our process development support covers upstream and downstream operations as one connected program. That includes clone and cell line selection, media and feed optimization, bioreactor parameter development, harvest strategy, Protein A capture, polishing chromatography, viral clearance design, and formulation planning. We also help teams identify critical quality attributes and link process decisions to product quality, so development work supports later analytical control, comparability, and lifecycle management.

As programs move toward clinical manufacturing and commercialization, we support scale-up, tech transfer, process characterization, and process validation planning with a focus on phase-appropriate CMC decisions. The goal is to build an mAb process that is technically sound, transferable, and ready to support IND, pivotal, and BLA-stage expectations.

DES Pharma provides consulting across every unit operation
from upstream cell culture through formulation.
The mAb Manufacturing Process Train

Cell Line Development

Clone selection and seed bank

Upstream Process

Media, feeds and bioreactor

Harvest and Clarification

Centrifuge and depth filtration

Protein A Capture

Affinity chromatography

Polishing

CEX / AEX / HIC steps

Viral Clearance

Nanofiltration & low pH

UF/DF & Formulation

DS concentration & buffer

Fill-Finish Interface

DP strategy & hold times

Phase-Appropriate Services mAb Process Development by
Development Stage

Our service model adapts to your program’s stage 
ensuring the right level of rigor, documentation, and investment at each milestone.

Building the mAb Process Foundation

Expression system selection, cell line development, and IND-enabling upstream and downstream process definition.

Optimizing for Clinical Manufacturing and Scale

Process refinement, GMP manufacturing support, tech transfer, and phase-appropriate CMC documentation.

Commercial Process Readiness and BLA Preparation

Late-stage process characterization, PPQ planning, comparability strategy, and BLA-ready CMC documentation.

mAb Process Expertise Deep Technical Capability Across the mAb Manufacturing Platform

Our process development consultants have hands-on experience with CHO-based commercial platforms, protein A purification design, polishing strategy, viral clearance qualification, and formulation development for concentration-sensitive mAb drug substances. We understand how process decisions at each stage propagate forward into CQA control, comparability, and regulatory expectations, and we bring that integrated perspective to every engagement.

We work alongside in-house process development scientists, technical operations teams, and CDMO partners, providing technical oversight, authoring study protocols and characterization reports, and ensuring that process knowledge is captured in a form that supports BLA-stage documentation and lifecycle management.

Why DES Pharma What We Bring to Your mAb
Process Program

Practical expertise, regulatory alignment, and CDMO-side experience,
applied to programs at every stage of the development lifecycle.

Upstream and Downstream Integration

We develop upstream and downstream as a connected program, ensuring that decisions in cell culture, glycan profiles, HCP levels, aggregation, are visible in purification design and CQA control strategy.

Phase-Calibrated Rigor

We apply the right level of characterization and documentation discipline for your stage, preventing over-investment early and ensuring sufficient process understanding exists before entering pivotal and commercial phases.

CQA-Linked Process Thinking

Every process decision is connected to its downstream impact on product quality attributes. We help teams build a mechanistic understanding that will support both regulatory review and lifecycle change management.

CDMO Technical Oversight

We know how CDMOs operate and where technical gaps emerge. We provide on-site or remote oversight for technology transfer, engineering runs, and GMP manufacturing campaigns across leading contract manufacturers.

Regulatory-Ready Documentation

Process development work is documented in formats that translate directly into IND CMC sections, BLA Module 3.2.S narratives, and PPQ protocols, reducing the gap between development and filing deliverables.

Lifecycle and Change Management

We design processes with post-approval flexibility in mind. Comparability frameworks, resin lifetime strategies, and raw material qualification approaches are built into the development program from the start.

Our Engagement Model How We Work on mAb
Process Programs

We integrate directly into your development team, whether you need a single expert to lead a specific workstream or a broader team to accelerate an entire CMC program. Engagements are structured around deliverables and milestones, not time-and-materials ambiguity.

Program Review and Gap Assessment

We review your existing process data, development history, and regulatory context to identify gaps relative to phase-appropriate expectations and your target CMC pathway.

Development Strategy and Work Plan

We define a prioritized process development roadmap covering key studies, decision points, timeline, and resourcing, integrated with your analytical and regulatory plans.

Technical Execution and Oversight

Our consultants lead or support study execution, directing CDMO activities, reviewing experimental data, interpreting results, and maintaining scientific rigor throughout development.

CMC Documentation and Regulatory Filing

Development reports, IND sections, and BLA Module 3 narratives are authored concurrently with the technical work, ensuring the filing package reflects the actual process understanding achieved.

Regulatory Framework

ICH Q11

Development and manufacture of drug substances, covers process selection, control strategy, and design space for mAb DS

ICH Q8(R2)

Pharmaceutical development, underpins DoE, design space definition, and process understanding documentation

ICH Q5A

Viral safety evaluation, governs clearance study design and documentation for mammalian cell-derived biologics

ICH Q5E

Comparability, framework for assessing impact of manufacturing changes on safety and efficacy

ICH Q6B

Specifications for biotechnological products, anchor for CQA selection, acceptance criteria, and control strategy

FDA Guidance

Q&A on Process Validation for Drug Substances & Drug Products, aligns process characterization with PPQ expectations

Get Started Build a Technically Sound, Transfer-Ready mAb Process

Whether you’re designing your first CHO process or preparing for PPQ and BLA submission, our consultants are ready to assess where your program stands and define the right path forward.